Timing of Rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis

Lignende værker

• Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases
  af: Quartuccio, Luca, et al.
  Udgivet: (2020)
• Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
  af: Stone, John H., et al.
  Udgivet: (2010)
• Rituximab for the Treatment of Relapses in ANCA-associated Vasculitis
  af: Miloslavsky, EM, et al.
  Udgivet: (2014)
• Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis
  af: McClure, Mark E., et al.
  Udgivet: (2019)
• PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
  af: van Dam, Laura S, et al.
  Udgivet: (2020)